The Future Trends in HIV Prevention and Treatment
The landscape of HIV prevention and treatment is evolving rapidly, driven by innovative medical advancements and advocacy efforts. Here’s a closer look at some of the most significant trends and developments.
The Advent of Injectable PrEP
One of the most recent and exciting developments is the introduction of injectable PrEP (Pre-exposure Prophylaxis). Injectable PrEP, namely the drug cabotegravir marketed as Apretude, was approved by Health Canada (in 2024) for the reduction of HIV risk through sexual exposure. Instead of taking a daily pill, patients can now receive injections every two months.
Tim Lagman, a sexual health educator and podcaster from Scarborough, Ontario, has been a proponent of this new approach. For Lagman, who has been taking oral PrEP since 2017, the idea of switching to an injectable form brings great relief. "Every other month would be a lot easier for me, my peace of mind and my schedule," he said, highlighting the convenience and flexibility of this option.
While Apretude is a promising step forward, the availability of this injectable PrEP differs across Canada. Quebec is currently the first and only province to cover its costs through its public prescription drug insurance plan. This move by Quebec has been hailed as a significant stride in preventing HIV, particularly for those who struggle with daily pill regimens.
Longer-Lasting Preventives and Treatments
Injectables aren’t the only innovation in HIV treatment and prevention. There are exciting trials on drugs to combat HIV, such as lenacapavir, which showed high effectiveness with injections just twice a year.
To give a clearer comparison, we have this table on prevention and treatment types.
| Treatment Type | Frequency | Brand Name or Drug | Level of Effectiveness |
|---|---|---|---|
| Oral PrEP | Daily | Descovy, Truvada | Moderate to High |
| Injectable PrEP | Every 2 Months | Apretude (Cabotegravir) | High |
| Injectable Treatment | Every 1-month | Cabenuva | High |
| Injectable Prevention | Twice a year | Lenacapavir | Very High |
If this progress can be replicated on a broader scale, it would provide even more flexibility for those at risk, making treatment more accessible and less disruptive to daily routines.
The Importance of Accessibility and Affordability
Despite these advancements, significant barriers still persist in the accessibility of screening, treatment, and prevention tools. The COVID-19 pandemic hindered HIV testing, resulting in a 35% increase in new infections in Canada between 2022 and 2023, as reported by the Public Health Agency of Canada. In contrast, global HIV incidents decreased by almost 22% in the same timeline, according to The Lancet HIV medical journal.
Expanding options for HIV screening and treatment is crucial for effective disease control. For example, the cost barrier remains a significant obstacle. While Quebec has taken the lead in covering injectable Apretude, many patients, even with private insurance, still bear out-of-pocket costs. Advocates like Dr. Darrel Tan from St. Michael’s Hospital believe the key to successful HIV management is ensuring that more people get the access and the support that accommodates their individual circumstances.
Advocating for accessible and affordable treatments such as injectable options and reducing global obstacles is essential for achieving the United Nations’ goal to end AIDS by 2030. Efforts include reconsidering U.S. foreign aid and improving local health infrastructure by improving testing and making screening confident.
Kent Monteith, the Executive Director of Quebec’s network of AIDS organizations, stated it aptly: “We want to make sure that people have all choices possible, so we are adapting their treatment to their lifestyle and not the other way around.”
FGA: Did You Know?
Injectable treatments and preventives offer significant advancements in HIV management, providing options that simplify adherence and better accommodate diverse needs.
however, making them "accessible," “affrodable,” and widely available to all populations, especially those vulnerable, remains a global challenge.
What Awaits in HIV Treatment in Prevention?
Injectable PrEP is just the first step in the rapid progress of HIV treatment technology. Furthering that, affordable testing, and wider health infrastructure in sensitive zones shall need judicious amounts of planning and political will by concerned and powerful leaders.
Call to Action
Explore more detailed articles on how you can best manage infections, make your community healthier using proactive tools, and take part in payment discussions on health care. Stay updated. Share your opinions in the comments and subscribe to our newsletter for latest articles.
